Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors

NCT07602855 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT07602855
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07602855 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Clinical Activity of Risvutatug Rezetecan in Combination With Ivonescimab in Participants With Advanced Solid Tumors
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Recruiting
Start date
September 9, 2026
Completion date
December 24, 2029
Enrollment
184 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

neoplasms, lung